Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis

• Published in: British journal of surgery Vol. 111; no. 5
• Main Authors: Guchelaar, Niels A D, Nasserinejad, Kazem, Mostert, Bianca, Koolen, Stijn L W, van der Sluis, Pieter C, Lagarde, Sjoerd M, Wijnhoven, Bas P L, Mathijssen, Ron H J, Noordman, Bo J
• Format: Journal Article
• Language: English
• Published: UK Oxford University Press 03.05.2024
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Docetaxel - administration & dosage; Humans; Infusions, Parenteral; Paclitaxel - administration & dosage; Palliative Care - methods; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - mortality; Peritoneal Neoplasms - secondary; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Systematic Review
• ISSN: 0007-1323; 1365-2168
• DOI: 10.1093/bjs/znae116

Abstract Background Gastric cancer with peritoneal metastases is associated with a dismal prognosis. Normothermic catheter-based intraperitoneal chemotherapy and normothermic pressurized intraperitoneal aerosol chemotherapy (PIPAC) are methods to deliver chemotherapy intraperitoneally leading to higher intraperitoneal concentrations of cytotoxic drugs compared to intravenous administration. We reviewed the effectiveness and safety of different methods of palliative intraperitoneal chemotherapy. Methods Embase, MEDLINE, Web of Science and Cochrane were searched for articles studying the use of repeated administration of palliative intraperitoneal chemotherapy in patients with gastric cancer and peritoneal metastases, published up to January 2024. The primary outcome was overall survival. Results Twenty-three studies were included, representing a total of 999 patients. The pooled median overall survival was 14.5 months. The pooled hazard ratio of the two RCTs using intraperitoneal paclitaxel and docetaxel favoured the intraperitoneal chemotherapy arm. The median overall survival of intraperitoneal paclitaxel, intraperitoneal docetaxel and PIPAC with cisplatin and doxorubicin were respectively 18.4 months, 13.2 months and 9.0 months. All treatment methods had a relatively safe toxicity profile. Conversion surgery after completion of intraperitoneal therapy was performed in 16% of the patients. Conclusions Repeated intraperitoneal chemotherapy, regardless of method of administration, is safe for patients with gastric cancer and peritoneal metastases. Conversion surgery after completion of the intraperitoneal chemotherapy is possible in a subset of patients. This study shows that repeated intraperitoneal chemotherapy, regardless of method of administration, is a promising and safe treatment for patients with gastric cancer and peritoneal metastases. Conversion surgery after completion of the intraperitoneal chemotherapy is possible in a selected subset of patients.